Wilke Michael-Holger, Rathmayer Markus
inspiring-health - Dr. Wilke GmbH, Munich, Germany.
Visc Med. 2016 Feb;32(1):29-35. doi: 10.1159/000443652. Epub 2016 Feb 9.
New procedures in endoscopy take time to be incorporated in the German diagnosis-related groups (DRG) system. Depending on the extent of innovation and the costs, several pathways are possible.
This article provides an overview of possible pathways to implement new procedures in the German DRG payment system. Additionally, we compare the results of 2 surveys on the system of New Diagnostic and Treatment Methods (Neue Untersuchungs- und Behandlungsmethoden; NUB). Furthermore, the pathways of 2 innovations in endoscopy are described in detail and compared with the possibilities within the legal framework.
The different pathways like NUB applications or DRG change requests and the underlying legal framework are described in detail. The results of a survey from 2007 on the daily practice of NUB funding in Germany show that the extent of innovations which receive a positive assessment (status 1) is 46% compared to 43.7% in a survey from 2007, and that 77% of the status 1 procedures (and drugs) can be negotiated into a payment - compared to 53% in the older survey.
Medical scientific societies should be involved in this process from the beginning. Besides the importance for the hospital application process (81.3% of all medical controllers want to have society support), the regulatory bodies (e.g. DIMDI, InEK, G-BA) also appreciate scientific statements. Two examples show the pathways in detail. For radiofrequency ablation of Barrett's esophagus, the pathway of continuous change requests was chosen, while the endoluminal conduit for the treatment of type 2 diabetes was established as NUB payment.
内镜检查的新程序需要时间才能纳入德国诊断相关分组(DRG)系统。根据创新程度和成本,可能有几种途径。
本文概述了在德国DRG支付系统中实施新程序的可能途径。此外,我们比较了关于新诊断和治疗方法(Neue Untersuchungs- und Behandlungsmethoden;NUB)系统的两项调查结果。此外,详细描述了内镜检查中两项创新的途径,并与法律框架内的可能性进行了比较。
详细描述了不同的途径,如NUB申请或DRG变更请求以及潜在的法律框架。2007年关于德国NUB资助日常实践的一项调查结果显示,获得积极评估(状态1)的创新程度为46%,而2007年的一项调查中为43.7%,并且77%的状态1程序(和药物)可以协商纳入支付——相比旧调查中的53%。
医学科学协会应从一开始就参与这一过程。除了对医院申请过程很重要(所有医疗管理人员中有81.3%希望得到协会支持)外,监管机构(如DIMDI、InEK、G-BA)也重视科学声明。两个例子详细展示了途径。对于巴雷特食管的射频消融,选择了持续变更请求的途径,而用于治疗2型糖尿病的腔内导管则被确定为NUB支付。